Erasca (ERAS) Retained Earnings (2020 - 2026)
Erasca posted quarterly Retained Earnings of -$1.1 billion for Q1 2026, down 171381.69% year-on-year from N/an in Q1 2025, and down 171381.69% on a QoQ basis from $628000.0 in Q4 2025.
Erasca (ERAS) has 7 years of Retained Earnings data on file, last reported at -$1.1 billion in Q1 2026.
- For the quarter ending Q1 2026, Retained Earnings fell 171381.69% year-over-year to -$1.1 billion; the trailing twelve-month figure through Mar 2026 stood at -$1.1 billion (down 171381.69% YoY), and the FY2025 full-year result was $628000.0, up 100.08% from the prior year.
- Retained Earnings for Q1 2026 stood at -$1.1 billion, down from $628000.0 in the prior quarter.
- Across five years, Retained Earnings topped out at $628000.0 in Q1 2025 and bottomed at -$1.1 billion in Q1 2026.
- The 5-year median for Retained Earnings is -$514.2 million (2023), against an average of -$433.4 million.
- The widest annual swing landed in 2023, when Retained Earnings jumped 107.4%; it then sank 997064.94% in 2024.
- A 5-year view of Retained Earnings shows it stood at -$1.0 million in 2022, then surged by 107.4% to $77000.0 in 2023, then tumbled by 997064.94% to -$767.7 million in 2024, then soared by 100.08% to $628000.0 in 2025, then sank by 171381.69% to -$1.1 billion in 2026.
- The last three Retained Earnings figures came in at -$1.1 billion (Q1 2026), $628000.0 (Q4 2025), and -$863.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Erasca | 4.21 Bn | 3.97 Bn | - | -1.08 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.08 Bn |
| Dec 31, 2025 | 628,000.00 |
| Sep 30, 2025 | -863.12 Mn |
| Jun 30, 2025 | -832.51 Mn |
| Mar 31, 2025 | 628,000.00 |
| Dec 31, 2024 | -767.66 Mn |
| Sep 30, 2024 | -735.40 Mn |
| Jun 30, 2024 | -704.23 Mn |
| Mar 31, 2024 | -641.03 Mn |
| Dec 31, 2023 | 77,000.00 |
| Sep 30, 2023 | -576.31 Mn |
| Jun 30, 2023 | -793,000.00 |
| Mar 31, 2023 | -514.20 Mn |
| Dec 31, 2022 | -1.04 Mn |
| Sep 30, 2022 | -345.70 Mn |
| Jun 30, 2022 | -310.23 Mn |
| Mar 31, 2022 | -951,000.00 |
| Dec 31, 2021 | -238.17 Mn |
| Sep 30, 2021 | -207.70 Mn |
| Jun 30, 2021 | -161.60 Mn |
| Dec 31, 2020 | -115.40 Mn |